These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 33823471)

  • 81. Is preoperative chemoradiation in rectal cancer patients modulated by ACE inhibitors? Results from the Dutch Cancer Registry.
    Rombouts AJ; Hugen N; Verhoeven RH; Kuiper JG; Poortmans PM; de Wilt JH; Nagtegaal ID
    Radiother Oncol; 2019 Sep; 138():86-92. PubMed ID: 31252299
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Combination with Angiotensin-Receptor Blockers in Nondiabetic Chronic Kidney Disease: A Systematic Review and Meta-Analysis.
    Zhao M; Ma S; Yu Y; Wang R; Chang M; Zhang H; Qu H; Zhang Y
    Curr Med Chem; 2021; 28(38):7961-7973. PubMed ID: 34126881
    [TBL] [Abstract][Full Text] [Related]  

  • 83. The role of the central renin-angiotensin system in Parkinson's disease.
    Mertens B; Vanderheyden P; Michotte Y; Sarre S
    J Renin Angiotensin Aldosterone Syst; 2010 Mar; 11(1):49-56. PubMed ID: 19861346
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Impact of drug price adjustments on utilization of and expenditures on angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in Taiwan.
    Huang SH; Hsu CN; Yu SH; Cham TM
    BMC Public Health; 2012 May; 12():288. PubMed ID: 22521158
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Primary prevention of myocardial infarction with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in hypertensive patients with rheumatoid arthritis-A nationwide cohort study.
    Lin TT; Wu CK; Liao MT; Yang YH; Chen PC; Yeih DF; Lin LY
    PLoS One; 2017; 12(12):e0188720. PubMed ID: 29216228
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Long-term beneficial effects of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker therapy for patients with advanced immunoglobulin A nephropathy and impaired renal function.
    Moriyama T; Amamiya N; Ochi A; Tsuruta Y; Shimizu A; Kojima C; Itabashi M; Takei T; Uchida K; Nitta K
    Clin Exp Nephrol; 2011 Oct; 15(5):700-707. PubMed ID: 21625892
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Protective Effect of Renin-Angiotensin System Inhibitors on Parkinson's Disease: A Nationwide Cohort Study.
    Jo Y; Kim S; Ye BS; Lee E; Yu YM
    Front Pharmacol; 2022; 13():837890. PubMed ID: 35308220
    [No Abstract]   [Full Text] [Related]  

  • 88. The Association of Visually Guided Saccades and DAT-SPECT Findings in Parkinson's Disease.
    Kobayashi M; Kuwabara S
    Eur Neurol; 2021; 84(2):110-118. PubMed ID: 33823506
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Opicapone in Parkinson's Disease: Real-World Data from a Portuguese Center.
    Meira-Carvalho F; Da Silva JD; Rodrigues M
    Eur Neurol; 2021; 84(2):129-131. PubMed ID: 33823522
    [No Abstract]   [Full Text] [Related]  

  • 90. Serum Neurofilament Dynamics Predicts Cognitive Progression in de novo Parkinson's Disease.
    Ma LZ; Zhang C; Wang H; Ma YH; Shen XN; Wang J; Tan L; Dong Q; Yu JT
    J Parkinsons Dis; 2021; 11(3):1117-1127. PubMed ID: 33935105
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Experimental Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of the Evidence.
    Müller T
    J Exp Pharmacol; 2021; 13():397-408. PubMed ID: 33824605
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Human-lineage-specific genomic elements are associated with neurodegenerative disease and APOE transcript usage.
    Chen Z; Zhang D; Reynolds RH; Gustavsson EK; García-Ruiz S; D'Sa K; Fairbrother-Browne A; Vandrovcova J; ; Hardy J; Houlden H; Gagliano Taliun SA; Botía J; Ryten M
    Nat Commun; 2021 Apr; 12(1):2076. PubMed ID: 33824317
    [TBL] [Abstract][Full Text] [Related]  

  • 93. The CD200R1 microglial inhibitory receptor as a therapeutic target in the MPTP model of Parkinson's disease.
    Rabaneda-Lombarte N; Serratosa J; Bové J; Vila M; Saura J; Solà C
    J Neuroinflammation; 2021 Apr; 18(1):88. PubMed ID: 33823877
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Disrupted morphological grey matter networks in early-stage Parkinson's disease.
    Suo X; Lei D; Li N; Li W; Kemp GJ; Sweeney JA; Peng R; Gong Q
    Brain Struct Funct; 2021 Jun; 226(5):1389-1403. PubMed ID: 33825053
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Effect of M. chamomilla L. tea on chlorpromazine induced catalepsy: A neuroprotective study.
    Khan SS; Ikram R; Naeem S; Khatoon H; Anser H; Sikander B
    Pak J Pharm Sci; 2020 Sep; 33(5):1945-1953. PubMed ID: 33824100
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Effect of the combination of automated peripheral mechanical stimulation and physical exercise on aerobic functional capacity and cardiac autonomic control in patients with Parkinson's disease: a randomized clinical trial protocol.
    Zelada-Astudillo N; Moreno VC; Herrera-Santelices A; Barbieri FA; Zamunér AR
    Trials; 2021 Apr; 22(1):250. PubMed ID: 33823928
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts.
    Leta V; Urso D; Batzu L; Weintraub D; Titova N; Aarsland D; Martinez-Martin P; Borghammer P; van Wamelen DJ; Yousaf T; Rizos A; Rodriguez-Blazquez C; Chung-Faye G; Chaudhuri KR
    J Parkinsons Dis; 2021; 11(3):1209-1219. PubMed ID: 33843697
    [TBL] [Abstract][Full Text] [Related]  

  • 98. The role of the brain renin-angiotensin system in Parkinson´s disease.
    Labandeira-Garcia JL; Labandeira CM; Guerra MJ; Rodriguez-Perez AI
    Transl Neurodegener; 2024 Apr; 13(1):22. PubMed ID: 38622720
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Antihypertensive drugs may not delay the symptom progression of Parkinson's disease: A 2-year follow-up study.
    Dong Z; Zuo R; Zhong X; Zhang C; Zou X; Tian Y; Zuo H; Du X; Yu Q; Cheng O
    Heliyon; 2023 Aug; 9(8):e18538. PubMed ID: 37560660
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Genetic polymorphisms in the renin-angiotensin system and cognitive decline in Parkinson's disease.
    Pierzchlińska A; Sławek J; Mak M; Gawrońska-Szklarz B; Białecka M
    Mol Biol Rep; 2021 Jul; 48(7):5541-5548. PubMed ID: 34302265
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.